Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2019; 19(2):93-97
DOI: 10.5428/pcar20190204
Effects of arsenic trioxide on migration and invasion of human ovarian cancer SKOV3 cells and study on related molecular mechanism
1. ZHOU Peng1(1.Teaching and Research Section of Pathophysiology,School of Basic Medicine,Navy Military Medical University,Shanghai 200433,China zhoupeng8118@163.com)
2. WANG Yan1(1.Teaching and Research Section of Pathophysiology,School of Basic Medicine,Navy Military Medical University,Shanghai 200433,China )
3. HUANG Gaoxiang1(1.Teaching and Research Section of Pathophysiology,School of Basic Medicine,Navy Military Medical University,Shanghai 200433,China )
4. LI Yidong1(1.Teaching and Research Section of Pathophysiology,School of Basic Medicine,Navy Military Medical University,Shanghai 200433,China liyidong2015@163.com)
5. 2(2.Basic Department of International Medical Technology College,Shanghai Shanda College,Shanghai 201209,China liyidong2015@163.com)
ABSTRACT  Objective: To investigate the effects of arsenic trioxide(As2O3) on ovarian cancer cell metastasis and study on related molecular mechanism.Methods: The effects of As2O3 on the migration and invasion of human ovarian cancer SKOV3 cells were observed by cell scratch,Transwell chamber and Matrigel Transwell cell(invasion chamber).Western blot method was used to detect tumor metastasis related proteins after As2O3 treatment at different time points,including the detection of Rho-related protein kinase(ROCK) and matrix metalloproteinase family(MMPs) protein expression.Results: As2O3(2 μmol/L) could significantly inhibit the migration and invasion of SKOV3 cells.The Western blot assay showed that As2O3 could significantly inhibit the expressions of ROCK1,ROCK2 and MMP-9,but had no obvious effect on the expression of MMP-2 could be observed.Conclusion: As2O3 could significantly inhibit the migration and invasion of human ovarian cancer SKOV3 cells,which might be related to the inhibition of the expressions of ROCK1,ROCK2 and MMP-9.
Welcome to PCAR! You are the number 211 reader of this article!
Please cite this article as:
ZHOU Peng1,WANG Yan1,HUANG Gaoxiang1,LI Yidong1,2,. Effects of arsenic trioxide on migration and invasion of human ovarian cancer SKOV3 cells and study on related molecular mechanism[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2019; 19(2): 93-97.
References:
1. Dugo E B,Yedjou C G,Stevens J J,et al. Therapeutic potential of arsenic trioxide(ATO) in treatment of hepatocellular carcinoma: role of oxidative stress in ATO-induced apoptosis[J]. Ann Clin Pathol,2017,5(1):1101.
2. Chen Z,Zhang H,Yang L,et al. Construction of a metabolomics profile of arsenic trioxide effect in gastric carcinoma cell line SGC7901[J]. Acta Biochim Biophys Sin(Shanghai),2016,48(5):474-481.
3. Ji H,Li Y,Jiang F,et al. Inhibition of transforming growth factor beta/SMAD signal by MiR-155 is involved in arsenic trioxide-induced anti-angiogenesis in prostate cancer[J]. Cancer Sci,2014,105(12):1541-1549.
4. Sadaf N,Kumar N,Ali M,et al. Arsenic trioxide induces apoptosis and inhibits the growth of human liver cancer cells[J]. Life Sci,2018,205:9-17.
5. Zhang F,Zhang C M,Li S,et al. Low dosage of arsenic trioxide inhibits vasculogenic mimicry in hepatoblastoma without cell apoptosis[J]. Mol Med Rep,2018,17(1):1573-1582.
6. Vanharanta S,Massagué J. Origins of metastatic traits[J]. Cancer Cell,2013,24(4):410-421.
7. vila-Rodriguez D,Solano Agama C,González-Pozos S,et al. The shift in GH3 cell shape and cell motility is dependent on MLCK and ROCK[J]. Exp Cell Res,2017,354(1):1-17.
8. Tang L,Dai F,Liu Y,et al. RhoA/ROCK signaling regulates smooth muscle phenotypic modulation and vascular remodeling via the JNK pathway and vimentin cytoskeleton[J]. Pharmacol Res,2018,133:201-212.
9. Falk P,Jonsson A,Swartling T,et al. Role of matrix metalloproteinases in tumour invasion: immunohistochemistry of peritoneum from peritoneal carcinomatosis[J].Med Oncol,2018,35(5):64.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口